静脉胺相比电治疗主要抑郁症或双极性抑郁症:随机对照试验的元分析
Zhan-Ming Shi1, Xian-Jun Lan2, Qing Chen3
1Chongqing Jiangbei Mental Health Center, Chongqing, China.
Journal of affective disorders
|November 16, 2024
概括
静脉注射胺 (IV) 显示出比电疗法 (ECT) 治疗严重抑郁症 (MDD) 或双极性抑郁症 (BD) 更快的抗抑郁作用. 长期有效性和安全性需要进一步的大规模试验.
科学领域:
- 精神病学和神经科学 精神病学和神经科学
- 药理学 药理学是指药理学的学科.
- 临床试验和元分析
背景情况:
- 大型抑郁症 (MDD) 和双极性抑郁症 (BD) 是重大的心理健康挑战.
- 电疗法 (ECT) 是一种成熟的治疗方法,但其与静脉注射胺 (IV胺) 等新药的比较疗效需要进一步研究.
- 对于MDD/BD的IV胺与ECT的现有研究已经产生了不确定的比较结果.
研究的目的:
- 系统地评估IV胺与ECT在治疗MDD或BD时的比较疗效,安全性和耐受性.
- 综合随机对照试验 (RCT) 的发现,比较这两种治疗方式.
主要方法:
- 一项对五项随机对照试验 (RCT) 的元分析,涉及664名患有MDD或BD的患者.
- 由三个独立调查人员提取数据,在随机效应模型下使用RevMan 5.3软件进行合成.
- 评估疗效 (减轻抑郁症状,反应,缓解) 和安全性 (不良事件,神经认知,停药率).
主要成果:
- 与ECT相比,IV胺在治疗后24小时显示出抑郁症状的统计显著减少 (SMD = -0.49,P = 0.04).
- 在治疗结束时响应或缓解率方面,IV胺和ECT之间没有发现显著差异.
- 静脉胺与分离和视觉障碍的增加有关,而ECT导致更多的肌肉疼痛;停药率相似.
结论:
- 与MDD/BD的ECT相比,IV胺提供了更快的抗抑郁作用.
- 这两种治疗方法在治疗期结束时都会产生可比的整体结果.
- 大规模的RCT是必要的,以充分确定IV胺相对于ECT的长期疗效和安全性.
相关概念视频
01:30Electroconvulsive Therapy
25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25
01:24Mania and Antimanic Drugs: Overview
136
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
136
01:23Antidepressant Drugs: MAOIs and Other Agents
195
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
195